Skip to content

A multicenter study on the efficacy and influencing factors of Insect Compound Particle in the treatment of MMR related stage III colorectal cancer

A multicenter study on the efficacy and influencing factors of Insect Compound Particle in the treatment of MMR related stage III colorectal cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037568
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Sponsors

Shanghai Municipal Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) According to the above diagnostic criteria, stage III colorectal cancer was diagnosed; (2) They agreed to accept radical operation, and were clinically diagnosed as tn1-2m0 after consultation, physical examination, laboratory examination and imaging examination; (3) Agree to collect colorectal cancer tissue samples, and agreed to carry out pathological test, MMR, RAS, malta1, NF2 gene detection and Merlin protein expression; (4) We agreed to collect peripheral blood for metabonomics analysis; (5) Aged >=18 years old; (6) The ECoG of the patients with an estimated survival time of more than 6 months was less than 2; (7) They agreed to be followed up; (8) The follow-up and clinical data were complete; (9) Those who voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Complicated with other primary malignant tumor; (2) Complicated with serious heart, brain, liver, kidney disease, electrolyte abnormality or mental illness; (3) Patients who are allergic to the drugs used in this study or their ingredients; (4) Pregnancy, lactation or planned pregnancy; (5) With serious or uncontrollable infections; (6) Those who took other traditional Chinese medicine or participated in other clinical trials in recent 2 weeks.

Design outcomes

Primary

MeasureTime frame
DFS;

Secondary

MeasureTime frame
OS;Safety-related physical and chemical indicators;TCM symptom score scale;Quality of life scale;

Countries

China

Contacts

Public ContactRen Jianlin

Shanghai Municipal Hospital of Traditional Chinese Medicine

renjianlin666@126.com+86 18116070881

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026